A unlimited special collection of a whole industry

Author:Kenji Bureau Time:2022.09.01

The national collection of insulin companies is not good.

On August 30, Tonghua Dongbao announced that the company achieved revenue of 1.388 billion yuan in the first half of 2022, a year -on -year decrease of 16.53%; non -profit of home deductions was 441 million yuan, a year -on -year decrease of 32.67%. In this regard, Tonghua Dongbao explained that the decline in the company's income and profits was due to the winning bid for insulin products throughout the line.

The long -acting insulin giant Gan Li Yaoye was not good in the first half of the year. The operating income fell 43.42%, only 835 million yuan, and the loss was 198 million yuan. This is the first half -year reporting loss since the listing of Ganli Yaoye.

Gan Li Pharmaceuticals attributed the cause of huge losses to the special collection of drugs across the country. The company announced that the six products of the company have won the bid at a high level and obtained a higher agreement. However effect.

Transnational pharmaceutical companies also feel "chill". According to the 2022 semi -annual report, Novo Nord won the 7 products in this collection, and its products occupied a large share in the Chinese market. The district business increased by 13.4%, but the company estimated that the sales of the two insulin -winning products fell by 30%.

The power of collection is fully appeared in the insulin product.

Domestic enterprise performance declines

For the result of insulin collection, domestic enterprises have long been expected.

Tonghua Dongbao previously released two performance trailers. On July 15, Tonghua Dongbao released the performance preview that the company's revenue is expected to decrease by 32.49 million yuan, a year -on -year decrease of about 4.96%.

Only 20 days later, Tonghua Dongbao released corrections, saying that the revenue is expected to decrease to 205 million yuan.

The two performance estimates before and after, so much deviation is not uncommon. Tonghua Dongbao explained that all the inventory products before the implementation of the collection need to return the difference to dealers in circulation.

The Jianzhi Bureau was informed that the downstream of Tonghua Dongbao involved 1054 commercial companies and 27,900 sales terminals. The insulin in the channels must be sold according to collecting price, and the company must subsidize these dealers. This has caused Tonghua Dongbao's operating income and net profit to both decline.

Ganli Pharmaceutical is a relatively active enterprise with a relatively active price reduction. The long -acting categorian glycry glycry insulin is 48.71 yuan, which is more than 30%cheaper than the same specifications of Sanofi, Tonghua Dongbao, and Zhuhai Federation. Sanofi had previously occupied the largest share of glyphosenic insulin in China. Gan Li Pharmaceutical obviously hopes to grab the market by collecting collection, so it has reported a ultra -low price.

Such a quotation strategy has put Gan Li Yaocai in the market passive. Ganli Pharmaceutical CEO Kai Kai said: At present, the selection results in insulin collection have just begun to be implemented. Doctors' prescription habits and diabetic patients need time to change. Bring short -term pain.

The original price of foreign -funded varieties such as Sanofi, Nuo and Nord, and the loss of price reductions is even greater. Rudo and Nord's ground special insulin prices are more than 200 yuan, and the price of mining is only 73 yuan.

In order to hedge the impact, Sanofi invested 200 million yuan as early as 2020 to expand the production base of Beijing insulin and cope with possible collection.

In addition, Chinese and foreign insulin companies seem to have no good way.

Feel the market "chill"

Insulin products have large bases and are relatively closed, and there are not many participating companies. For this type of product, the "seven inches" of the industry have been integrated.

Conservative estimates that the national insulin market sales have been close to 400 million, while the scale of the national insulin special collection is 210 million, accounting for only 50%of the total.

It is precisely because of the large patient base that the State Medical Insurance Bureau can calmly carry out collective collection. Gan Li, Tonghua Dongbao, Nuo and Nuo Nuo, Cyri, Eli Lili and other companies have to deal with prices. There are many market spaces.

Jiji not only reduces the retail price of insulin products, but is based on prices, which streamlines the entire industrial chain such as production, wholesale, and retail.

Since March of this year, Tonghua Dongbao has moved to the retail market, deployed national e -commerce channels, and has been carried out in offline pharmacies in 20 provinces to increase the investment in foreign markets such as retail channels and private hospitals and offset as soon as possible. The impact of national collection on the company's performance. Ganli Pharmaceutical chose "internationalization", and its door winter insulin was approved to enter the Kazakhstan and Bangladesh market. At present, Ganli Pharmaceutical has been sold in 14 countries.

Throughout the current status of the existing diabetic medication market, the second and third -generation insulin is the leading product, and the national collection mainly focuses on the second -generation insulin. On the whole, the status of the three generations of insulin multinational pharmaceutical companies is still firm. Nuo and Nuo, Lilly, and Sanofi, the three multinational pharmaceutical companies account for 70%of the market, and it will take time to achieve the "domestic alternative" strategy.

As for why the "price replacement" that the national collection has always advocated is not performed on the variety of insulin? The industry believes that the cost of clinical use of products, commercial channels, and drug distribution links cannot be reduced. This is the main reason why insulin collection fails to generate positive benefits quickly.

Tonghua Dongbao once stated on the interactive platform that it is necessary to reasonably reduce some sales costs and expand professional sales teams outside the collection to strive for higher market share.In August of this year, Gan Li Pharmaceutical said on the investor interactive platform that the company's academic promotion team continued to expand.Regarding the problem of the second generation of the second generation, Tonghua Dongbao once told the Jianzhi Bureau that although this is a major trend, the second -generation insulin users are not "which one is cheap", but based on the doctor's guidance.

Ji Cai has made a bottom of China ’s 140 million diabetic patients. Whether it can achieve“ domestic replacement ”can also be achieved, and it also requires the efforts of Chinese enterprises.

The Kenji Bureau was informed that the response methods of foreign-funded enterprises include: Novaro is pushing new products such as GLP-1, and at the same time expand indications; Sanofi tries to use expansion to reduce costs.

Writing ｜ Xiaomi